검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | XGEVA® |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Giant Cell Tumor of Bone |
Overview Indication | Castration-resistant Prostate Cancer; Metastatic Cancer |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | targets and binds with high affinity and specificity to receptor |
MoA Biomarker | Biomarkers, and Emerging Therapies |
PK/PD Species | Mouse, Rabbit, Comparison of pharmacokinetics, pharmacodynamics, safety |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rabbit, Comparison of pharmacokinetics, pharmacodynamics, safety |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men.. This Phase 1 study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety of INTP23.1, a proposed denosumab biosimilar, compared with US- and EU-licensed reference denosumab… |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT00556374 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | XGEVA® |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Giant Cell Tumor of Bone |
Overview Indication | Castration-resistant Prostate Cancer; Metastatic Cancer |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | targets and binds with high affinity and specificity to receptor |
MoA Biomarker | Biomarkers, and Emerging Therapies |
PK/PD Species | Mouse, Rabbit, Comparison of pharmacokinetics, pharmacodynamics, safety |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rabbit, Comparison of pharmacokinetics, pharmacodynamics, safety |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men.. This Phase 1 study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety of INTP23.1, a proposed denosumab biosimilar, compared with US- and EU-licensed reference denosumab… |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT00556374 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교